AOP	Adverse Outcome Pathway
API	Active Pharmaceutical Ingredient
ATEX	Explosive Atmospheres
ATMP	Advanced Therapy Medicinal Products
CPC	Condensation Particle Counter
CWA	CEN Workshop Agreement
DDD	Drug Discovery and Development
ECHA	European Chemicals Agency
EFM	Environmental Fate Models
EFSA	European Food Safety Authority
EMA	European Medicines Agency
ENM	engineered nanomaterial
ERA	environmental risk assessment
FDA	Food and Drug Administration
FTIR	Fourier transform infrared spectroscopy
GMP	Good Manufacturing Practice
IATA	Integrated Approaches to Testing and Assessment
ICP-MS	Inductively Coupled Plasma-Mass Spectrometry
LAL	Limulus amebocyte lysate
MCDA	Multicriteria Decision Analysis
MD	Medical Device
MFA	Material Flow Analysis
MHLW	Ministry of Health, Labour and Welfare
NBM	nano-biomaterial
OECD	Organisation for Economic Co-operation and Development
PAC	Process Analytical Control
PBPK	Physiologically Based Pharmacokinetic
PEC	Predicted Environmental Concentrations
PhRMA BRAT	Pharmaceutical Research and Manufacturers of America, the Benefit-Risk Action Team
PNEC	Predicted No-Effect Concentrations
PrOACT-URL	Problem formulation, Objectives, Alternatives Consequences, Trade-offs, Uncertainties, Risk tolerance
QA	Quality Assurance
QSAR	Quantitative Structure Activity Relationship
REACH	Registration, Evaluation, Authorisation and restriction of Chemicals
RMF	Risk Management Framework
RMM	Risk Management Measures
RMP	Risk Management Plan
R&D	Research and Development
SbD	Safe-by-Design
SbMD	safe by material design
SbPD	safety by process design
S&E	Safety and Efficacy
SEM	Scanning Electron Microscopy
SMPS	Scanning Mobility Particle Sizer
TEM	Transmission Electron Microscopy
UMBRA	Universal Methodology for Benefit-Risk Assessment
UN/GHS	United Nations Globally Harmonized System of Classification and Labelling of Chemicals